Edward Salopek
Family Medicine · Charleroi, PANPI 1457341745
Payments from drug & device makers
Across 127 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$736
- Novo Nordisk$276
- Lilly USA, LLC$276
- Amgen$161
- Abbott$160
- Pfizer$156
- plus $394 from 13 others
What the payments were for
- Food & beverage$2,158100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $736 |
| Novo Nordisk | 15 | $276 |
| Lilly USA, LLC | 17 | $276 |
| Amgen | 10 | $161 |
| Abbott | 9 | $160 |
| Pfizer | 11 | $156 |
| AstraZeneca | 8 | $125 |
| Shield Therapeutics Inc | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Bayer | 2 | $27 |
| Edwards Lifesciences | 1 | $26 |
| AbbVie | 1 | $24 |
| Astellas Pharma US Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$2,158 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $108,799 |
| RybelsusSemaglutide | 57 | $93,595 |
| JardianceEmpagliflozin | 75 | $88,297 |
| EliquisApixaban | 100 | $78,539 |
| FarxigaDapagliflozin Propanediol | 76 | $70,922 |
| TrulicityDulaglutide | 33 | $45,159 |
| OzempicSemaglutide | 37 | $44,010 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $43,556 |
| XareltoRivaroxaban | 38 | $27,809 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $17,128 |
| Repatha SureclickEvolocumab | 27 | $16,538 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $16,495 |
| TradjentaLinagliptin | 21 | $16,252 |
| JanuviaSitagliptin Phosphate | 17 | $15,939 |
| MyrbetriqMirabegron | 16 | $13,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $736 | $185,979211 claims |
| Novo NordiskRybelsus, Ozempic | $276 | $137,60594 claims |
| PfizerEliquis, Premarin | $156 | $81,545113 claims |
| AstraZenecaFarxiga | $125 | $70,92276 claims |
| Lilly USA, LLCTrulicity | $276 | $45,15933 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $13,05816 claims |
| AbbVieLinzess | $24 | $11,25813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Charleroi
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.